Novartis, Bayer Settle IP Spat Over Hemophilia Drugs

Law360, New York (February 23, 2010, 4:59 PM EST) -- The vaccines division of Swiss drugmaker Novartis AG has reached a settlement and licensing deal with Bayer HealthCare LLC in a patent infringement suit over Bayer hemophilia drugs Kogenate and Helixate.

Novartis Vaccines and Diagnostics Inc. and co-plaintiff Novo Nordisk A/S joined defendants Bayer and CSL Behring LLC on Tuesday in asking the U.S. District Court for the Eastern District of Texas to dismiss the case with prejudice.

The parties said they had reached a confidential settlement and licensing agreement that called for both sides to...
To view the full article, register now.